ABIVAX Société Anonyme's (ABVX) Market Outperform Rating Reiterated at JMP Securities

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s stock had its "market outperform" rating reaffirmed by JMP Securities in a note issued to investors on Wednesday,Benzinga reports. They presently have a $33.00 price objective on the stock. JMP Securities' price objective would suggest a potential upside of 358.97% from the company's current price.

Separately, Morgan Stanley reiterated an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $34.00.

ABIVAX Société Anonyme Stock Up 4.1 %

Shares of ABVX stock traded up $0.28 during mid-day trading on Wednesday, hitting $7.19. The company's stock had a trading volume of 138,291 shares, compared to its average volume of 132,187. ABIVAX Société Anonyme has a 52-week low of $4.77 and a 52-week high of $15.10. The business has a 50-day moving average price of $6.60 and a 200 day moving average price of $7.54.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently modified their holdings of ABVX. GAMMA Investing LLC lifted its stake in shares of ABIVAX Société Anonyme by 373.6% in the 1st quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock valued at $118,000 after purchasing an additional 14,855 shares during the period. Two Sigma Investments LP purchased a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth about $144,000. Stonepine Capital Management LLC acquired a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at about $110,000. Shay Capital LLC purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $366,000. Finally, Millennium Management LLC raised its holdings in ABIVAX Société Anonyme by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company's stock worth $6,816,000 after purchasing an additional 285,542 shares during the period. Institutional investors and hedge funds own 47.91% of the company's stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.